Literature DB >> 1730874

IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor.

P Ralph1, I Nakoinz, A Sampson-Johannes, S Fong, D Lowe, H Y Min, L Lin.   

Abstract

We have identified and purified a factor that inhibits the production of IL-1 beta and TNF by stimulated human mononuclear cells. The activity is produced by the T cell lines Hut-78 and Mo constitutively under serum-free conditions. Crude conditioned media have titers of up to 100 U/ml (one unit defined as the reciprocal of the dilution producing 50% inhibition). The activity resides mainly in a single size peak of 30 to 35 kDa and an isoelectric point around 8. Other cytokines in this size range that have been reported to be inhibitory for IL-1 and TNF production include TGF-beta, IL-4, and IL-6; these factors were excluded by lack of detection, neutralizing antibody, and low activity compared with our factor. Another factor with these size and charge properties is IL-10, which inhibits T cell cytokine production. By polymerase chain reaction analysis, Mo and HuT-78 lines contain IL-10 transcripts whereas JURKAT is negative; this correlates with inhibitor bioactivity from the three lines. Use of mAb specifically showed the inhibitor to be IL-10.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730874

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

Review 1.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

2.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Modulation of virus-induced delayed-type hypersensitivity by plasmid DNA encoding the cytokine interleukin-10.

Authors:  E Manickan; M Daheshia; N Kuklin; S Chun; B T Rouse
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

Review 4.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 6.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

7.  Production of interleukin-10 by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; M D Burdick; C A Wilke; M B Orringer; R I Whyte; R M Strieter
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

8.  Treatment with anti-interleukin-10 monoclonal antibody enhances early resistance to but impairs complete clearance of Listeria monocytogenes infection in mice.

Authors:  R D Wagner; N M Maroushek; J F Brown; C J Czuprynski
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

Review 9.  Cautionary insights on knockout mouse studies: the gene or not the gene?

Authors:  Amy F Eisener-Dorman; David A Lawrence; Valerie J Bolivar
Journal:  Brain Behav Immun       Date:  2008-09-12       Impact factor: 7.217

10.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.